الصفحة الرئيسية>>Signaling Pathways>> Others>>KMH-233

KMH-233

رقم الكتالوجGC61845

KMH-233 ، مثبط 1 (LAT1) قوي وقابل للعكس وانتقائي لنقل الأحماض الأمينية ، يمنع امتصاص LAT1 الركيزة ، l-leucin (IC50 = 18 ميكرومتر) وكذلك نمو الخلايايعمل KMH-233 على تقوية فعالية Bestatin و Cisplatin بشكل كبير حتى بتركيزات منخفضة (25 ميكرومتر)

Products are for research use only. Not for human use. We do not sell to patients.

KMH-233 التركيب الكيميائي

Cas No.: 1941174-13-5

الحجم السعر المخزون الكميّة
5 mg
1305٫00
متوفر
10 mg
2205٫00
متوفر
25 mg
4365٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KMH-233, a potent, reversible and selective l-type amino acid transporter 1 (LAT1) inhibitor, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 µM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 µM)[1].

KMH-233 is able to inhibit binding and transport of essential neutral amino acids and thus, inhibit the cell growth of cancer cells[1].KMH-233 shows a significant reduction of cell growth with an IC50 of 124 µM[1].KMH-233 is effective and able to potentiate the anti-proliferative efficacy of Bestatin (100 µM) and Cisplatin (100 µM) at a lower concentration of 25 µM, inhibiting cell growth 53% and 50%, respectively[1].

References:
[1]. Huttunen KM, et al. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. J Med Chem. 2016;59(12):5740-5751.

مراجعات

Review for KMH-233

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KMH-233

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.